Written question asked by Sharon Hodgson (Labour) on Friday, 31 January 2020, in the House of Commons. It was due for an answer on Tuesday, 4 February 2020. It was answered by Jo Churchill (Conservative) on Monday, 10 February 2020 on behalf of the Department of Health and Social Care.
Atezolizumab and Nab-paclitaxel
- Question
-
To ask the Secretary of State for Health and Social Care, what meetings representatives of (a) NICE and (b) NHS England have had with Roche on atezolizumab with nab-paclitaxel for breast cancer patients since the publication of NICE's draft guidance on that drug in October 2019.
- Answer
-
NHS England and NHS Improvement has advised that it has met with Roche to discuss potential commercial arrangements for atezolizumab with nab-paclitaxel for breast cancer patients.
The National Institute for Health and Care Excellence (NICE) has advised that it held a telephone call with Roche on 23 January 2020 regarding atezolizumab with nab-paclitaxel for breast cancer patients and that it has been in contact with Roche by email since the publication of NICE's draft guidance in October 2019.
Secondary information
- Type
- Written question
- Reference
- 10749
- Session
- 2019-21
- Subjects
- Roche Atezolizumab Nab-paclitaxel
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2023-11-03 14:37:48 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2019-20/10749
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2019-20/10749
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2019-20/10749